{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:00:49Z","timestamp":1793736049998,"version":"4.6.1"},"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/501100023280","name":"CSL Seqirus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2692245","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:22:23Z","timestamp":1782757343000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the cost-effectiveness of adjuvanted influenza vaccine in the older adult population in the Netherlands"],"prefix":"10.1080","volume":"22","author":[{"given":"Susan","family":"de Braak","sequence":"first","affiliation":[{"name":"Health-Ecore","place":["Zeist, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin F.","family":"Mould-Quevedo","sequence":"additional","affiliation":[{"name":"CSL Seqirus","place":["Summit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Wilschut","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen","place":["Groningen, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit A.","family":"van Essen","sequence":"additional","affiliation":[{"name":"Dutch Immunisation Foundation","place":["Amersfoort, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Osterhaus","sequence":"additional","affiliation":[{"name":"University of Veterinary Medicine","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[{"name":"Health-Ecore","place":["Zeist, the Netherlands"]},{"name":"University of Groningen, University Medical Center Groningen","place":["Groningen, the Netherlands"]},{"name":"University of Groningen","place":["Groningen, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Zeevat","sequence":"additional","affiliation":[{"name":"Health-Ecore","place":["Zeist, the Netherlands"]},{"name":"University of Groningen, University Medical Center Groningen","place":["Groningen, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.21945\/RIVM-2024-0135"},{"key":"e_1_3_5_3_1","unstructured":"Nederlands Huisartsen Genootschap (NHG). Praktijkhandleiding Griepvaccinatie. 2025 [accessed 2025 Jul 7]. https:\/\/www.nhg.org\/praktijkvoering\/vaccinatieprogrammas\/praktijkhandleiding-griepvaccinatie\/%EF%BB%BF\/."},{"key":"e_1_3_5_4_1","unstructured":"CDC. Types of influenza viruses. Influenza (flu). 2024 Sep 27 [accessed 2025 Jul 7]. https:\/\/www.cdc.gov\/flu\/about\/viruses-types.html."},{"key":"e_1_3_5_5_1","unstructured":"Reukers DFM Van Asten L Hooiveld M. Surveillance of acute respiratory infections in the Netherlands: winter 2022\/2023. National Institute for Public Health and the Environment (RIVM); 2023."},{"key":"e_1_3_5_6_1","unstructured":"CBS. Ziekenhuisopnamen en -pati\u00ebnten; diagnose-indeling ICD-10 (3-teken niveau). 2025 [accessed 2025 Jul 8]. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/84069NED\/table."},{"key":"e_1_3_5_7_1","unstructured":"NIVEL. Vaccine coverage Dutch national influenza prevention program 2021: brief monitor.2025 [accessed 2023 Nov 22]. https:\/\/www.nivel.nl\/en\/publicatie\/vaccine-coverage-dutch-national-influenza-prevention-program-2021-brief-monitor."},{"key":"e_1_3_5_8_1","unstructured":"Ministerie van Volksgezondheid Welzijn en Sport. Advies inzet van vernieuwde typen griepvaccins in het NPG - Advies - Gezondheidsraad. 2024 [accessed 2025 Jul 11]. https:\/\/www.gezondheidsraad.nl\/documenten\/adviezen\/2024\/12\/17\/advies-inzet-van-vernieuwde-typen-griepvaccins-in-het-npg."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201602-095AW"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.70020"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12871"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16950"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12050523"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11061089"},{"key":"e_1_3_5_15_1","unstructured":"EMA. Fluad INN-influenza vaccine (surface antigen inactivated adjuvanted). 2025 [accessed 2025 Aug 21]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fluad-epar-product-information_en.pdf."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13030323"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881800273X"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.013"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2018.10.001"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.21945\/RIVM-2020-0177"},{"key":"e_1_3_5_21_1","unstructured":"Preventie op waarde schatten - Advies technische werkgroep kosten en baten van preventie. Kennisplatform Preventie; 2023 [accessed 2025 May 25]. https:\/\/open.overheid.nl\/documenten\/92ad7df5-0b1f-4dcc-b7f1-efb7cd6ee6b5\/file."},{"key":"e_1_3_5_22_1","unstructured":"CBS. Bevolking op 1 januari en gemiddeld; geslacht leeftijd en regio. 2025 [accessed 2024 Sep 11]. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/03759ned\/table?dl=39E0B."},{"key":"e_1_3_5_23_1","unstructured":"Ministerie van Volksgezondheid Welzijn en Sport. Monitor vaccinatiegraad Nationaal Programma Grieppreventie (NPG) 2023 - rapport - Rijksoverheid.nl. 2024 Sep 30 [accessed 2025 May 19]. https:\/\/www.rijksoverheid.nl\/documenten\/rapporten\/2024\/09\/30\/monitor-vaccinatiegraad-nationaal-programma-grieppreventie-npg-2023."},{"key":"e_1_3_5_24_1","unstructured":"Volksgezondheid en Zorg. Chronische aandoeningen en multimorbiditeit | Leeftijd en geslacht. 2025 [accessed 2025 Aug 12]. https:\/\/www.vzinfo.nl\/chronische-aandoeningen-en-multimorbiditeit\/leeftijd-en-geslacht."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.040"},{"key":"e_1_3_5_26_1","unstructured":"Tacken M Jansen B Mulder J Tiersma W Braspenning J. Monitoring vaccinatiegraad Nationaal Programma Grieppreventie 2013. LINH; 2014."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.013"},{"key":"e_1_3_5_28_1","unstructured":"Centraal Bureau voor de Statistiek. Statline - consumentenprijzen; prijsindex 2015=100. 2025 [accessed 2025 Dec 8]. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/83131NED\/table."},{"key":"e_1_3_5_29_1","unstructured":"Hakkaart-van Roijen L Peeters S Kanters T. Kostenhandleiding voor economische evaluaties in de gezondheidszorg: methodologie en Referentieprijzen. 2024."},{"key":"e_1_3_5_30_1","unstructured":"Vergoeding. SNPG. [accessed 2025 May 19]. https:\/\/www.snpg.nl\/article\/griep-ha-afronden\/declareren-griepvaccinaties\/vergoeding\/."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.21945\/RIVM-2018-0049"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13146"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586130-000000000-00000"},{"key":"e_1_3_5_34_1","unstructured":"ISPOR. Principles of good practice for budget impact analysis II. 2025 [accessed 2025 Sep 19]. https:\/\/www.ispor.org\/heor-resources\/good-practices\/article\/principles-of-good-practice-for-budget-impact-analysis-ii."},{"key":"e_1_3_5_35_1","unstructured":"CBS. Prognose bevolking; kerncijfers 2021-2070. 2025 [accessed 2025 Sep 19]. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/85089NED\/table."},{"key":"e_1_3_5_36_1","unstructured":"Laarman C Heins M Knottnerus B Stelma F Hooiveld M NIVEL. Vaccine coverage Dutch national influenza prevention program 2023: brief monitor. 2024. https:\/\/www.nivel.nl\/en\/publicatie\/vaccine-coverage-dutch-national-influenza-prevention-program-2023-brief-monitor."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00844-y"},{"key":"e_1_3_5_38_1","unstructured":"Zorginstituut Nederland. Kostenhandleiding voor het uitvoeren van economische evaluaties in de gezondheidszorg (versie 2024) - Publicatie - Zorginstituut Nederland. Ministerie van Volksgezondheid Welzijn en Sport; 2024 [accessed 2024 May 24]. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg."},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01426-6"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2702.202999"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100327"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-025-01219-x"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01742-8"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2499728"},{"key":"e_1_3_5_45_1","unstructured":"CSL Seqirus. A phase 3 randomized observer blind controlled multicenter clinical study to evaluate immunogenicity and safety of ahigh-dose MF59-adjuvanted quadrivalent subunit cell-derived influenza vaccine (aQivc HD). 2025. https:\/\/ichgcp.net\/clinical-trials-registry\/NCT06015282."},{"key":"e_1_3_5_46_1","unstructured":"Ministerie van Financi\u00ebn - Rijksoverheid. 6.2 Zorguitgaven in vogelvlucht. 2025 [accessed 2025 Sep 19]. https:\/\/www.rijksfinancien.nl\/memorie-van-toelichting\/2026\/OWB\/XVI\/onderdeel\/9894709."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1971017"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040753"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091386"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2229917"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12506"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.011"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2692245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2026.2692245","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2692245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:22:49Z","timestamp":1782757369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2692245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2692245"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2692245","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2692245"}}